Oak Harbor Wealth Partners LLC Has $385,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Oak Harbor Wealth Partners LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 206.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,737 shares of the medical device company’s stock after buying an additional 3,862 shares during the period. Oak Harbor Wealth Partners LLC’s holdings in DexCom were worth $385,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of DexCom by 15.7% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 12,841 shares of the medical device company’s stock valued at $861,000 after buying an additional 1,740 shares in the last quarter. Metis Global Partners LLC grew its holdings in shares of DexCom by 14.5% during the 3rd quarter. Metis Global Partners LLC now owns 21,166 shares of the medical device company’s stock worth $1,419,000 after acquiring an additional 2,684 shares during the period. Brooktree Capital Management purchased a new stake in DexCom during the 3rd quarter valued at $683,000. ICICI Prudential Asset Management Co Ltd raised its holdings in DexCom by 19.8% in the 3rd quarter. ICICI Prudential Asset Management Co Ltd now owns 5,231 shares of the medical device company’s stock worth $351,000 after purchasing an additional 863 shares during the period. Finally, Simmons Bank grew its position in shares of DexCom by 9.2% during the third quarter. Simmons Bank now owns 4,095 shares of the medical device company’s stock valued at $275,000 after purchasing an additional 345 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on DXCM shares. Morgan Stanley dropped their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. Oppenheimer cut their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Barclays reduced their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. Raymond James dropped their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by corporate insiders.

DexCom Price Performance

Shares of DXCM opened at $74.68 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The firm has a market capitalization of $29.17 billion, a PE ratio of 44.72, a P/E/G ratio of 2.22 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a 50 day simple moving average of $69.77 and a 200 day simple moving average of $92.14.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.